Strabismus management in retinoblastoma survivors.

Chemotherapy Retinoblastoma Strabismus Surgery

Journal

BMC ophthalmology
ISSN: 1471-2415
Titre abrégé: BMC Ophthalmol
Pays: England
ID NLM: 100967802

Informations de publication

Date de publication:
13 Mar 2024
Historique:
received: 19 02 2023
accepted: 04 03 2024
medline: 14 3 2024
pubmed: 14 3 2024
entrez: 14 3 2024
Statut: epublish

Résumé

To report the result of strabismus surgery in eye-salvaged retinoblastoma (Rb) patients. A retrospective case series including 18 patients with Rb and strabismus who underwent strabismus surgery after completing tumor treatment by a single pediatric ophthalmologist. A total of 18 patients (10 females and 8 males) were included with a mean age of 13.3 ± 3.0 (range, 2-39) months at the time tumor presentation and 6.0 ± 1.5 (range, 4-9) years at the time of strabismus surgery. Ten (56%) patients had unilateral and 8(44%) had bilateral involvement and the most common worse eye tumor's group was D (n = 11), C (n = 4), B (n = 2) and E (n = 1). Macula was involved by the tumors in 12 (67%) patients. The tumors were managed by intravenous chemotherapy (n = 8, 47%), intra-arterial chemotherapy (n = 7, 41%) and both (n = 3, 17%). After complete treatment, the average time to strabismus surgery was 29.9 ± 20.5 (range, 12-84) months. Except for one, visual acuity was equal or less than 1.0 logMAR (≤ 20/200) in the affected eye. Seven (39%) patients had exotropia, 11(61%) had esotropia (P = 0.346) and vertical deviation was found in 8 (48%) cases. The angle of deviation was 42.0 ± 10.4 (range, 30-60) prism diopter (PD) for esotropic and 35.7 ± 7.9 (range, 25-50) PD for exotropic patients (P = 0.32) that after surgery significantly decreased to 8.5 ± 5.3 PD in esotropic cases and 5.9 ± 6.7 PD in exotropic cases (P < 0.001). The mean follow-up after surgery was 15.2 ± 2.0 (range, 10-24) months, in which, 3 (17%) patients needed a second surgery. Strabismus surgery in treated Rb is safe and results of the surgeries are acceptable and close to the general population. There was not associated with tumor recurrence or metastasis.

Identifiants

pubmed: 38481156
doi: 10.1186/s12886-024-03379-9
pii: 10.1186/s12886-024-03379-9
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

114

Informations de copyright

© 2024. The Author(s).

Références

Kivelä T. The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death. Br J Ophthalmol. 2009;93(9):1129–31.
doi: 10.1136/bjo.2008.150292 pubmed: 19704035
Shields CL, Mashayekhi A, Au AK, et al. The International classification of Retinoblastoma predicts chemoreduction success. Ophthalmology. 2006;113(12):2276–80.
doi: 10.1016/j.ophtha.2006.06.018 pubmed: 16996605
Shields CL, Jorge R, Say EA, et al. Unilateral Retinoblastoma Managed with Intravenous Chemotherapy Versus Intra-arterial Chemotherapy. Outcomes based on the International classification of Retinoblastoma. Asia Pac J Ophthalmol. 2016;5(2):97–103.
doi: 10.1097/APO.0000000000000172
Batra A, Pushker N, Venkatesh P, Arora T, Tewari R, Bakhshi S. Long-term visual outcomes in intraocular retinoblastoma with eye preservation. Clin Transl Oncol. 2016;18:1034–8.
doi: 10.1007/s12094-016-1482-4 pubmed: 26781471
Hall LS, Ceisler E, Abramson DH. Visual outcomes in children with bilateral retinoblastoma. J AAPOS. 1999;3(3):138–42.
doi: 10.1016/S1091-8531(99)70058-3 pubmed: 10428586
Demirci H, Shields CL, Meadows AT, Shields JA. Long-term visual outcome following chemo reduction for retinoblastoma. Arch Ophthalmol. 2005;123(11):1525–30.
doi: 10.1001/archopht.123.11.1525 pubmed: 16286614
Schefler AC, Cicciarelli N, Feuer W, Toledano S, Murray TG. Macular Retinoblastoma: evaluation of Tumor Control, local complications, and visual outcomes for eyes treated with chemotherapy and repetitive foveal laser ablation. Ophthalmology. 2007;114(1):162–9.
doi: 10.1016/j.ophtha.2006.06.042 pubmed: 17070578
Abramson DH, Frank CM, Susman M, Whalen MP, Dunkel IJ, Boyd NW. Presenting signs of retinoblastoma. J Pediatr. 1998;132(3 I):505–8.
doi: 10.1016/S0022-3476(98)70028-9 pubmed: 9544909
Parks MM. Pediatric ophthalmology and I. Surv Ophthalmol. 1991 Jul-Aug;36(1):70– 6.
MacCarthy A, Birch JM, Draper GJ, et al. Retinoblastoma: treatment and survival in Great Britain 1963 to 2002. Br J Ophthalmol. 2009;93(1):38–9.
doi: 10.1136/bjo.2008.139626 pubmed: 18838414
Watts P, Westall C, Colpa L, et al. Visual results in children treated for macular retinoblastoma. Eye. 2002;16(1):75–80.
doi: 10.1038/sj.eye.6700070 pubmed: 11913894
Fabian ID, Naeem Z, Stacey AW, et al. Long-term visual acuity, Strabismus, and Nystagmus Outcomes Following Multimodality Treatment in Group D Retinoblastoma Eyes. Am J Ophthalmol. 2017;179:137–44.
doi: 10.1016/j.ajo.2017.05.003 pubmed: 28501391
Fabian ID, Stacey AW, Naeem Z, et al. Strabismus in retinoblastoma survivors with long-term follow-up. J AAPOS. 2018;22(4):276. e1-276.e7.
doi: 10.1016/j.jaapos.2018.03.007
Jackson S, Harrad RA, Morris M, Rumsey N. The psychosocial benefits of corrective surgery for adults with strabismus. Br J Ophthalmol. 2006;90(7):883–8.
doi: 10.1136/bjo.2005.089516 pubmed: 16782950 pmcid: 1857157
Akbari MR, Masoomian B, Ameri A, Keshtkar Jaafari A, Mirmohammadsadeghi A. Development of a Persian Version of the adult Strabismus Questionnaire and evaluating the Effect of Strabismus surgery on Health-Related Quality of Life. Strabismus. 2015;23(2):66–72.
doi: 10.3109/09273972.2015.1025986 pubmed: 26158472
Wang X, Gao X, Xiao M, et al. Effectiveness of strabismus surgery on the health-related quality of life assessment of children with intermittent exotropia and their parents: a randomized clinical trial. J AAPOS. 2015;19(4):298–303.
doi: 10.1016/j.jaapos.2015.04.007 pubmed: 26235788
Hatt SR, Leske DA, Liebermann L, et al. Associations between health-related quality of life and the decision to perform surgery for childhood intermittent exotropia. Ophthalmology. 2014;121(4):883–8.
doi: 10.1016/j.ophtha.2013.10.029 pubmed: 24314840
Yamada T, Hatt SR, Leske DA, Holmes JM. Health-related quality of life in parents of children with intermittent exotropia. J AAPOS. 2011;15:135–9.
doi: 10.1016/j.jaapos.2010.11.020 pubmed: 21419677 pmcid: 3098901
Koç İ, Taylan Şekeroğlu H, Kıratlı H, Lotfisadigh S. Management of cataracts secondary to intravitreal chemotherapy injections for retinoblastoma seeding. Eur J Ophthalmol. 2022;32(3):1766–71.
doi: 10.1177/11206721211023317 pubmed: 34082595
Payne JF, Hutchinson AK, Hubbard GB 3rd, Lambert SR. Outcomes of cataract surgery following radiation treatment for retinoblastoma. J AAPOS. 2009;13:454–8.
doi: 10.1016/j.jaapos.2009.06.002 pubmed: 19840723 pmcid: 3033780
Osman IM, Abouzeid H, Balmer A, et al. Modern cataract surgery for radiation-induced cataracts in retinoblastoma. Br J Ophthalmol. 2011;95:227–30.
doi: 10.1136/bjo.2009.173401 pubmed: 20576779
Kaliki S, Maniar A, Kekunnaya R. Cataract surgery in treated retinoblastoma eyes: a study of 29 eyes. Eur J Ophthalmol. 2021;31(4):2048–54.
doi: 10.1177/1120672120938575 pubmed: 32586135
Mohan K, Sharma A. A comparison of ocular alignment success of hang-back versus conventional bilateral lateral rectus muscle recession for true divergence excess intermittent exotropia. J AAPOS. 2013;17(1):29–33.
doi: 10.1016/j.jaapos.2012.09.014 pubmed: 23352721
Capó H, Repka MX, Guyton DL. Hang-back lateral rectus recessions for exotropia. J Pediatr Ophthalmol Strabismus. 1989;26(1):31–4.
doi: 10.3928/0191-3913-19890101-08 pubmed: 2915310
Gusek-Schneider G, Boss A. Results following eye muscle surgery for secondary sensory strabismus. Strabismus. 2010;18(1):24–31.
doi: 10.3109/09273971003623582 pubmed: 20230204
Merino P, Mateos C, De Gómez P, et al. [Horizontal sensory strabismus: characteristics and treatment results]. Arch Soc Esp Oftalmol. 2011;86(11):358–62.
doi: 10.1016/j.oftal.2011.05.028 pubmed: 22040642

Auteurs

Babak Masoomian (B)

Ocular Oncology Department, Farabi Eye HospitalFarabi Eye Hospital, Farabi Hospital, Tehran University of Medical Sciences, South Kargar Street, Qazvin square, Tehran, Iran. dr.masoomian@yahoo.com.
Pediatric Ophthalmology Department, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran. dr.masoomian@yahoo.com.

Carol L Shields (CL)

Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA, USA.

Hamid Riazi Esfahani (HR)

Ocular Oncology Department, Farabi Eye HospitalFarabi Eye Hospital, Farabi Hospital, Tehran University of Medical Sciences, South Kargar Street, Qazvin square, Tehran, Iran.

Atefeh Khalili (A)

Pediatric Ophthalmology Department, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.

Fariba Ghassemi (F)

Ocular Oncology Department, Farabi Eye HospitalFarabi Eye Hospital, Farabi Hospital, Tehran University of Medical Sciences, South Kargar Street, Qazvin square, Tehran, Iran.

Pukhraj Rishi (P)

Truhlsen Eye Institute, Omaha, NE, USA.

Mohammad Reza Akbari (MR)

Pediatric Ophthalmology Department, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.

Masoud Khorrami-Nejad (M)

School of Rehabilitation, Tehran University of Medical Sciences, Tehran, Iran.

Classifications MeSH